Existing drugs offer potential treatment for AKI
Scottish researchers uncovered that drugs used to treat angina and high blood pressure, could be used to treat AKI.
List view / Grid view
Scottish researchers uncovered that drugs used to treat angina and high blood pressure, could be used to treat AKI.
Japanese researchers showed for the first time processes that are crucial targets for treating liver cancer are enhanced by saturated fatty acid diets.
Despite decades without vaccine development in the respiratory syncytia virus (RSV) space, researchers are now homing in on a potential strategy to protect individuals from this disease. Here, Drug Target Review’s Ria Kakkad spoke with Dr Christy Comeaux, Medical Lead (RSV), Janssen, about the challenges associated with RSV vaccine development and her most promising…
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
Japanese researchers proposed using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama Muscular Dystrophy (FCMD).
US researchers have discovered a link between protein misfolding and liver cancer, that could help improve gene therapy for haemophilia.
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
This application note discusses why CAR T-cell therapy is so exciting, notes some common hurdles in development and manufacturing and proposes ddPCR technology as a solution for some of these issues.
Researchers have detected Alongshan virus (ALSV) for the first time in Switzerland in ticks.
Discover key target cells for immunotherapy, how cells and processes can be assessed in vitro and approaches for selecting the most appropriate assay.
This article outlines three innovative studies that use nanotechnology to deliver a new immunotherapy approach towards cancers.
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
Blocking a process called trogocytosis could enhance the ability of CAR T-cell therapies to treat cancer, according to research led by University of Pennsylvania scientists. In this Q&A, Dr Serge Fuchs, Elizabeth and William Whitney Clark Professor of Oncology at the University of Pennsylvania School of Veterinary Medicine, US, discusses…